A victory for the company's controversial prostate cancer treatment, but more debate lies ahead.
This entry was posted
on Tuesday, April 14th, 2009 at 4:32 pm and is filed under Uncategorized.
You can follow any responses to this entry through the RSS 2.0 feed.
Both comments and pings are currently closed.